Skip to main content

Stoke Therapeutics, Inc.

corporate_fare Company Profile

Stoke Therapeutics, Inc.

STOK·NASDAQ·Life Sciences·CIK 0001623526

The company is a late-stage clinical company focused on treating severe diseases by increasing protein expression using RNA-based medicines. They use their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) that selectively restore protein levels. Their primary investigational medicine, zorevunersen (STK-001), is a potential disease-modifying medicine in late-stage clinical testing for Dravet syndrome. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged, and refractory seizures starting within the first year of life, and is associated with developmental delays and cognitive impairment. There are currently no approved disease-modifying medicines for Dravet syndrome, which is one of many diseases caused by haploinsufficiency, where a loss of approximately 50% of normal protein levels leads to the disease. The company initially focuses on haploinsufficiencies and diseases of the central nervous system and the eye, with proof of concept also demonstrated in other organs, tissues, and systems. Zorevunersen is being evaluated in their global Phase 3 clinical study, EMPEROR, which began in May 2025, with the first patient dosed in August 2025. This study follows two completed open-label Phase 1/2a studies, MONARCH in the United States and ADMIRAL in the United Kingdom, and assesses zorevunersen's efficacy and safety in children and adolescents aged 2 to 18 with Dravet syndrome.

Stoke Therapeutics, Inc. (NASDAQ:STOK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for STOK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for STOK spans 10-Q, 144, 424B5, 8-K.

Recent high-impact activity:

  • Stoke 10-Q: $358.8M Cash Into Early 2028, Q3 Loss Widens to $73.6M
  • Stoke Posts $73.6M Q3 Loss as Dravet Phase 3 Nears Readout, Cash Runs to Early 2028
  • Former Director Kaye Notices Sale of 1.5M Shares (~$38M) After Option Exercise
  • FDA Aligns on Zorevunersen NDA Plan, Stoke Eyes 2028 Launch
  • Stoke's Zorevunersen Shows Durable Seizure and Cognitive Gains in 4-Year Dravet Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$184.42M
Net Income
-$6.88M
Diluted EPS
-$0.12
Op. Cash Flow
$45.59M
Free Cash Flow
$44.91M
Operating Income
-$20.59M
Cash & Equivalents
$84.22M
Debt / Equity
0.00×
Net Margin
-3.7%
Shares Outstanding
58.92M sh
Source: 10-K · filed 2026-03-16 · accession 0001193125-26-108362

Short Interest & Short Volume

6.75 days to cover

FINRA reported short interest of 10,722,415 shares in STOK as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 6.8 days to cover at its recent average daily volume. On November 20, 2026, 72.6% of STOK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,722,415 shares as of October 30, 2026
Change vs prior period▲ 4.5%
Days to cover6.75 at avg daily volume of 1,588,157
Daily short volume (FINRA facilities)72.6% of 164,553 shares on November 20, 2026
5-day average short volume66.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for STOK, detected from its recent SEC filings · based on capital-structure filings through 2026-08-03.

1 recent capital raiseATM program

ATM Program Upsized to $200M · Prior Sales Total $146.4M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$27.4 +2.20% today
52-week range · as of 2026-11-03 $20.32 – $40.22
Market cap
$1.75B
Volume
615.8K (0.5× avg)
3-mo avg 1.1M
Live data · 2026-11-22 07:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed STOK - Latest Insights

STOK
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.99
Real-time Price: $27.40 info
Change: +$0.410 (+2%) info
Market Cap: $1.754B info
STOK
Oct 29, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.36
Real-time Price: $27.40 info
Change: +$1.04 (+4%) info
Market Cap: $1.754B info
STOK
Oct 21, 2026, 4:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $27.40 info
Change: +$1.72 (+7%) info
Market Cap: $1.754B info
STOK
Oct 05, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $25.62
Real-time Price: $27.40 info
Change: +$1.78 (+7%) info
Market Cap: $1.754B info
STOK
Sep 03, 2026, 7:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $29.99
Real-time Price: $27.40 info
Change: -$2.59 (-9%) info
Market Cap: $1.754B info
STOK
Aug 03, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.95
Real-time Price: $27.40 info
Change: -$0.550 (-2%) info
Market Cap: $1.754B info
STOK
Aug 03, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $29.56
Real-time Price: $27.40 info
Change: -$2.16 (-7%) info
Market Cap: $1.754B info
STOK
Jun 30, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $32.39
Real-time Price: $27.40 info
Change: -$4.99 (-15%) info
Market Cap: $1.754B info
STOK
Jun 30, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.39
Real-time Price: $27.40 info
Change: -$4.99 (-15%) info
Market Cap: $1.754B info
STOK
May 07, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.79
Real-time Price: $27.40 info
Change: -$5.39 (-16%) info
Market Cap: $1.754B info
STOK
May 07, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $30.98
Real-time Price: $27.40 info
Change: -$3.58 (-12%) info
Market Cap: $1.754B info
STOK
May 07, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.51
Real-time Price: $27.40 info
Change: -$6.11 (-18%) info
Market Cap: $1.754B info
STOK
Mar 18, 2026, 4:06 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $30.73
Real-time Price: $27.40 info
Change: -$3.33 (-11%) info
Market Cap: $1.754B info
STOK
Mar 16, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $33.11
Real-time Price: $27.40 info
Change: -$5.71 (-17%) info
Market Cap: $1.754B info
STOK
Jan 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.25
Real-time Price: $27.40 info
Change: -$1.85 (-6%) info
Market Cap: $1.754B info
STOK
Jan 12, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.00
Real-time Price: $27.40 info
Change: -$1.60 (-6%) info
Market Cap: $1.754B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets